Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02310867

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation.

Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients from 18-65 years old with loss of limb
  • Willingness and legal ability to give informed consent
  • Willingness to travel to study site for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail

Exclusion criteria

  • Any condition that precludes serial follow-up
  • Any condition that would likely increase the risk of protocol participation or confound the interpretation of the data
  • Any active malignancy or any history of a malignancy or lymphoma
  • Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s)

Treatment and study plan

Belatacept

Drug

This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.

Other names: Nulojix

Hand transplant

Procedure

The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.

Primary outcomes

  1. Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

    Time frame: 18 months

Secondary outcomes

  1. Clinical rejection

    Time frame: 18 months

    Presence of macroscopic changes in the skin like a rash

  2. Histological rejection

    Time frame: 18 months

    Presence of infiltrates categorized by the Banff classification

Study contacts

Contact information is provided by the study sponsor or research team.

Linda Cendales, MD

CONTACT

[email protected]

919-681-7514

Sponsors and collaborators

Lead sponsor

Linda Cendales

Other

Registry information

Important dates

Study start
2015
Primary completion
2027
Study completion
2028
First posted
Dec 8, 2014
Registry last updated
Apr 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.